Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
This proposed rule primarily concerns Medicare hospital outpatient and ambulatory surgical center payment systems for CY 2027 and has minimal direct relevance to the peptide research supply industry. The only tangentially related provision is the expansion of prior authorization requirements for Botulinum Toxin injection services, which affects clinical Medicare billing rather than research peptide supply.
No action required for peptide research suppliers. Clinical providers billing Medicare for Botulinum Toxin injections should note the expanded prior authorization requirements and may submit comments during the public comment period.
Jan 1, 2027
Alert created: Jul 7, 2026, 1:00 PM